vs

Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Rubrik, Inc. (RBRK). Click either name above to swap in a different company.

EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $350.2M, roughly 1.7× Rubrik, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -18.2%, a 59.1% gap on every dollar of revenue. On growth, Rubrik, Inc. posted the faster year-over-year revenue change (48.3% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $80.7M).

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Rubrik, Inc. is an American cloud data management and data security company based in Palo Alto, California, founded in January 2014. The company is listed on the New York Stock Exchange after going public in April 2024.

EXEL vs RBRK — Head-to-Head

Bigger by revenue
EXEL
EXEL
1.7× larger
EXEL
$598.7M
$350.2M
RBRK
Growing faster (revenue YoY)
RBRK
RBRK
+42.6% gap
RBRK
48.3%
5.6%
EXEL
Higher net margin
EXEL
EXEL
59.1% more per $
EXEL
40.8%
-18.2%
RBRK
More free cash flow
EXEL
EXEL
$251.6M more FCF
EXEL
$332.4M
$80.7M
RBRK

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
EXEL
EXEL
RBRK
RBRK
Revenue
$598.7M
$350.2M
Net Profit
$244.5M
$-63.8M
Gross Margin
95.6%
80.5%
Operating Margin
39.3%
-21.6%
Net Margin
40.8%
-18.2%
Revenue YoY
5.6%
48.3%
Net Profit YoY
74.8%
51.2%
EPS (diluted)
$0.89
$-0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXEL
EXEL
RBRK
RBRK
Q1 26
$598.7M
Q4 25
$597.8M
$350.2M
Q3 25
$568.3M
$309.9M
Q2 25
$555.4M
$278.5M
Q1 25
$566.8M
$258.1M
Q4 24
$236.2M
Q3 24
$539.5M
$205.0M
Q2 24
$637.2M
$187.3M
Net Profit
EXEL
EXEL
RBRK
RBRK
Q1 26
$244.5M
Q4 25
$193.6M
$-63.8M
Q3 25
$184.8M
$-95.9M
Q2 25
$159.6M
$-102.1M
Q1 25
$139.9M
$-114.9M
Q4 24
$-130.9M
Q3 24
$118.0M
$-176.9M
Q2 24
$226.1M
$-732.1M
Gross Margin
EXEL
EXEL
RBRK
RBRK
Q1 26
95.6%
Q4 25
96.9%
80.5%
Q3 25
96.6%
79.5%
Q2 25
96.5%
78.3%
Q1 25
96.5%
77.4%
Q4 24
76.2%
Q3 24
96.8%
73.1%
Q2 24
97.2%
48.8%
Operating Margin
EXEL
EXEL
RBRK
RBRK
Q1 26
39.3%
Q4 25
39.6%
-21.6%
Q3 25
37.6%
-30.5%
Q2 25
33.6%
-33.4%
Q1 25
28.8%
-45.0%
Q4 24
-52.8%
Q3 24
25.2%
-82.1%
Q2 24
43.3%
-387.0%
Net Margin
EXEL
EXEL
RBRK
RBRK
Q1 26
40.8%
Q4 25
32.4%
-18.2%
Q3 25
32.5%
-31.0%
Q2 25
28.7%
-36.7%
Q1 25
24.7%
-44.5%
Q4 24
-55.4%
Q3 24
21.9%
-86.3%
Q2 24
35.5%
-390.8%
EPS (diluted)
EXEL
EXEL
RBRK
RBRK
Q1 26
$0.89
Q4 25
$0.69
$-0.32
Q3 25
$0.65
$-0.49
Q2 25
$0.55
$-0.53
Q1 25
$0.47
$5.69
Q4 24
$-0.71
Q3 24
$0.40
$-0.98
Q2 24
$0.77
$-11.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXEL
EXEL
RBRK
RBRK
Cash + ST InvestmentsLiquidity on hand
$1.1B
$307.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.2B
$-524.4M
Total Assets
$2.8B
$2.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXEL
EXEL
RBRK
RBRK
Q1 26
$1.1B
Q4 25
$988.5M
$307.1M
Q3 25
$791.1M
$322.7M
Q2 25
$1.0B
$284.0M
Q1 25
$1.1B
$186.3M
Q4 24
$103.9M
Q3 24
$1.2B
$142.3M
Q2 24
$1.0B
$502.6M
Stockholders' Equity
EXEL
EXEL
RBRK
RBRK
Q1 26
$2.2B
Q4 25
$2.2B
$-524.4M
Q3 25
$2.0B
$-564.3M
Q2 25
$2.1B
$-556.5M
Q1 25
$2.2B
$-553.7M
Q4 24
$-521.1M
Q3 24
$2.3B
$-499.3M
Q2 24
$2.1B
$-514.6M
Total Assets
EXEL
EXEL
RBRK
RBRK
Q1 26
$2.8B
Q4 25
$2.8B
$2.5B
Q3 25
$2.7B
$2.4B
Q2 25
$2.8B
$1.5B
Q1 25
$2.9B
$1.4B
Q4 24
$1.3B
Q3 24
$3.0B
$1.2B
Q2 24
$2.8B
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXEL
EXEL
RBRK
RBRK
Operating Cash FlowLast quarter
$333.5M
$85.5M
Free Cash FlowOCF − Capex
$332.4M
$80.7M
FCF MarginFCF / Revenue
55.5%
23.1%
Capex IntensityCapex / Revenue
0.2%
1.4%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$875.8M
$256.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXEL
EXEL
RBRK
RBRK
Q1 26
$333.5M
Q4 25
$290.3M
$85.5M
Q3 25
$49.0M
$64.7M
Q2 25
$211.4M
$39.7M
Q1 25
$240.3M
$83.6M
Q4 24
$23.1M
Q3 24
$271.3M
$-27.1M
Q2 24
$119.5M
$-31.4M
Free Cash Flow
EXEL
EXEL
RBRK
RBRK
Q1 26
$332.4M
Q4 25
$288.8M
$80.7M
Q3 25
$46.2M
$61.2M
Q2 25
$208.5M
$36.8M
Q1 25
$236.3M
$78.0M
Q4 24
$18.0M
Q3 24
$263.1M
$-29.7M
Q2 24
$113.0M
$-35.0M
FCF Margin
EXEL
EXEL
RBRK
RBRK
Q1 26
55.5%
Q4 25
48.3%
23.1%
Q3 25
8.1%
19.8%
Q2 25
37.5%
13.2%
Q1 25
41.7%
30.2%
Q4 24
7.6%
Q3 24
48.8%
-14.5%
Q2 24
17.7%
-18.7%
Capex Intensity
EXEL
EXEL
RBRK
RBRK
Q1 26
0.2%
Q4 25
0.2%
1.4%
Q3 25
0.5%
1.1%
Q2 25
0.5%
1.0%
Q1 25
0.7%
2.2%
Q4 24
2.1%
Q3 24
1.5%
1.3%
Q2 24
1.0%
1.9%
Cash Conversion
EXEL
EXEL
RBRK
RBRK
Q1 26
1.36×
Q4 25
1.50×
Q3 25
0.27×
Q2 25
1.32×
Q1 25
1.72×
Q4 24
Q3 24
2.30×
Q2 24
0.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXEL
EXEL

Cabometyx$544.7M91%
Collaboration$52.1M9%
Collaborative Arrangementwith Takeda$5.9M1%
Cometriq$1.8M0%

RBRK
RBRK

Subscription And Circulation$336.4M96%
Other$12.3M4%
Software And Services$4.9M1%
Maintenance$1.5M0%

Related Comparisons